Search

Your search keyword '"Shroff RT"' showing total 72 results

Search Constraints

Start Over You searched for: Author "Shroff RT" Remove constraint Author: "Shroff RT"
72 results on '"Shroff RT"'

Search Results

1. SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.

2. Clinical and Genomic Features of Classical and Basal Transcriptional Subtypes in Pancreatic Cancer.

4. Treatment options for biliary tract cancer: unmet needs, new targets and opportunities from both physicians' and patients' perspectives.

5. The room where it happens: addressing diversity, equity, and inclusion in National Clinical Trials Network clinical trial leadership.

6. Independent of Primary Sclerosing Cholangitis and Cirrhosis, Early Adulthood Obesity Is Associated with Cholangiocarcinoma.

7. Comparative Genomic Analysis of Pancreatic Acinar Cell Carcinoma (PACC) and Pancreatic Ductal Adenocarcinoma (PDAC) Unveils New Actionable Genomic Aberrations in PACC.

8. Multiomic Characterization Reveals a Distinct Molecular Landscape in Young-Onset Pancreatic Cancer.

9. The Cholangiocarcinoma in the Young (CITY) Study: Tumor Biology, Treatment Patterns, and Survival Outcomes in Adolescent Young Adults With Cholangiocarcinoma.

10. Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma.

11. Multi-omic characterization reveals a distinct molecular landscape in young-onset pancreatic cancer.

13. The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer.

14. Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015.

15. Decision-Making Regarding Perioperative Therapy in Individuals with Localized Pancreatic Adenocarcinoma.

16. Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis.

17. Precision Medicine in Biliary Tract Cancer.

18. Cholangiocarcinoma: a review of the literature and future directions in therapy.

19. COVID-19 Vaccines and Immunosuppressed Patients With Cancer: Critical Considerations.

20. Phase II Study of Ramucirumab in Advanced Biliary Tract Cancer Previously Treated By Gemcitabine-Based Chemotherapy.

21. Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures.

22. Novel biomarkers and the future of targeted therapies in cholangiocarcinoma: a narrative review.

23. Liquid biopsy, using a novel DNA methylation signature, distinguishes pancreatic adenocarcinoma from benign pancreatic disease.

24. Monitoring of Dynamic Changes and Clonal Evolution in Circulating Tumor DNA From Patients With IDH -Mutated Cholangiocarcinoma Treated With Isocitrate Dehydrogenase Inhibitors.

25. The immunogenomic landscape of resected intrahepatic cholangiocarcinoma.

26. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors.

27. Current and emerging therapies for advanced biliary tract cancers.

28. Final Overall Survival Efficacy Results of Ivosidenib for Patients With Advanced Cholangiocarcinoma With IDH1 Mutation: The Phase 3 Randomized Clinical ClarIDHy Trial.

29. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging.

30. Immune Responses to COVID-19 mRNA Vaccines in Patients with Solid Tumors on Active, Immunosuppressive Cancer Therapy.

31. Biliary cancer: gateway to comprehensive molecular profiling.

32. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline.

33. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma.

34. What is the role of PARP inhibitors in pancreatic cancer?

35. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma.

36. New Treatment Options for Advanced Biliary Tract Cancer.

37. Pancreatic cancer.

38. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.

39. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older.

40. Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Patients with Pancreatic Cancer.

42. Biliary tract cancers: systemic therapy for advanced disease.

43. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia.

44. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers.

46. Evaluation of the safety and effectiveness of direct oral anticoagulants and low molecular weight heparin in gastrointestinal cancer-associated venous thromboembolism.

47. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study.

48. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial.

49. Adjuvant Therapy for Resected Biliary Tract Cancer: ASCO Clinical Practice Guideline.

50. A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma.

Catalog

Books, media, physical & digital resources